MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of yttrium-90 microspheres


Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the absorbed dose in matter and tissue resulting from the exposure to indirect and direct ionising radiation.

Currently, PET or SPECT images are obtained after treatment to verify the distribution of microspheres. Now, absorbed dose from the Y-90 microspheres can be calculated on a voxel-by-voxel basis using the PET or SPECT images.

MIM SurePlan LiverY90 provides timesaving tools for liver and tumour segmentation, deformable registration, and allows patient-specific dose calculation on yttrium-90 (Y-90) PET and Bremsstrahlung SPECT images after administration of permanent Y-90 microspheres, a press release from the company states. The absorbed dose can be calculated for tumours and the liver to help provide important additional information to the clinician.

Three methods are available for dose calculation: Local Deposition Model, Local Deposition Model with scaling for known injected activity, and the Voxel S Value approach based on the schema in MIRD Pamphlet No. 17. All three methods are available for PET while only the Local Deposition Model with scaling for known activity is available for SPECT images that are not in Becquerel per milliliter (Bq/ml).

MIM Software will demonstrate MIM SurePlan LiverY90 at the 2017 Radiological Society of North America (RSNA) annual meeting 26–30 November in Chicago, USA. Attendees wishing to view a demonstration can visit booth 8108.

In October 2016, BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy and facilitate personalised treatment for patients with liver cancer.


Please enter your comment!
Please enter your name here